



01-25-10

Attorney's Docket No.: 3800024.00350/1111US

1FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lin Zhi et al.
Serial No. : 10/566,569
Filed : August 21, 2006

Art Unit : 1625
Examiner : D. Margaret Seaman
Conf. No. : 6058
Cust. No. : 77202

Title : 6-CYCLOAMINO-2-QUINOLINONE DERIVATIVES AS ANDROGEN
RECEPTOR MODULATOR COMPOUNDS

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement (3 pages), Form PTO-1449 (1 page), cited non U.S. patent documents listed on the form PTO-1449 (1 volume), documents listed in table of Supplemental Information Disclosure Statement (1 volume), and a return postcard for filing in connection with the above-captioned application. The Commissioner is hereby authorized to charge the fee for the Information Disclosure Statement to Deposit Account No. 02-1818.



The Commissioner is hereby authorized to charge the fee for filing the Information Disclosure Statement and any other fee that may be due in connection with this and the attached papers or with this application during its entire pendency to Deposit Account No. 02-1818. A duplicate of this sheet is enclosed

Respectfully submitted,

Stephanie Seidman
Reg. No. 33,779

Attorney's Docket No.: 3800024.00350/1111US
Address all correspondence to: 77202
Stephanie Seidman
K&L Gates LLP
3580 Carmel Mountain Road, Suite 200
San Diego, California 92130
Telephone: (858) 509-7410
Facsimile: (858) 509-7460
email: stephanie.seidman@klgates.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"Express Mail" Mailing Label Number EM 315455766 US.
Date of Deposit January 20, 2010.

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Jon Levy



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lin Zhi et al.
Serial No. : 10/566,569
Filed : August 21, 2006

Art Unit : 1625
Examiner : D. Margaret Seaman
Conf. No. : 6058
Cust. No. : 77202

Title : 6-CYCLOAMINO-2-QUINOLINONE DERIVATIVES AS ANDROGEN
RECEPTOR MODULATOR COMPOUNDS

Mail Stop: Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement (3 pages), Form PTO-1449 (1 page), cited non U.S. patent documents listed on the form PTO-1449 (1 volume), documents listed in table of Supplemental Information Disclosure Statement (1 volume), and a return postcard for filing in connection with the above-captioned application.

The Commissioner is hereby authorized to charge the fee for the Information Disclosure Statement to Deposit Account No. 02-1818.



The Commissioner is hereby authorized to charge the fee for filing the Information Disclosure Statement and any other fee that may be due in connection with this and the attached papers or with this application during its entire pendency to Deposit Account No. 02-1818. A duplicate of this sheet is enclosed

Respectfully submitted,

Stephanie Seidman
Reg. No. 33,779

Attorney's Docket No.: 3800024.00350/1111US

Address all correspondence to: 77202

Stephanie Seidman

K&L Gates LLP

3580 Carmel Mountain Road, Suite 200

San Diego, California 92130

Telephone: (858) 509-7410

Facsimile: (858) 509-7460

email: stephanie.seidman@klgates.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number EM 315455766 US.

Date of Deposit January 20, 2010.

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Jon Levy



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lin Zhi et al.
Serial No. : 10/566,569
Filed : August 21, 2006
Art Unit : 1625
Examiner : D. Margaret Seaman
Conf. No. : 6058
Cust. No. : 77202
Title : 6-CYCLOAMINO-2-QUINOLINONE DERIVATIVES AS ANDROGEN
RECEPTOR MODULATOR COMPOUNDS

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN
ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98**

Dear Sir:

Because this Supplemental Information Disclosure Statement is filed after the receipt of a First Office Action on the Merits for the above-captioned application, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 02-1818.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and copies of the cited non U.S. Patent documents are provided herewith in connection with the above-captioned application.

The documents cited on the Forms PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, this Supplemental Information Disclosure Statement (sIDS) includes Office Actions issued in connection with corresponding Foreign Patent Applications (Documents 1-3), and another documents, a subsequent publication by inventors of this application:

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"Express Mail" Mailing Label Number EM 315455766 US.
Date of Deposit January 20, 2010.
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.


Jon Levy

1) Office Action, issued May 25, 2009, in connection with Australian Patent Application No. 2004266160 (Attorney Docket No. 3800024.00340/1111AU).

2) Office Action (English translation), issued July 31, 2009, in connection with Chinese Patent Application No. 200480024125.2 (Attorney Docket No. 3800024.00343/1111CN).

3) Office Action (English translation), issued October 6, 2009, in connection with Japanese Patent Application No. 2006-524121 (Attorney Docket No. 3800014.00347/1111JP).

The table below lists Documents 1-4 and includes a column that provides a space for the Examiner's initials next to the document to be considered. This Supplemental Information Disclosure Statement includes the application number of the application in which the sIDS is being submitted, a column that provides a blank space next to each citation for the Examiner's initials, a heading on the listing that clearly indicates the list is an Information Disclosure Statement, and copies of Documents 1-4. Therefore, this sIDS is in compliance with 37 CFR §§ 1.97, 1.98 and MPEP § 609 and Applicant respectfully requests that Examiner consider and initial all information listed in the table below.

Examiner Initial	Document No.	Document
	1	Office Action, issued May 25, 2009, in connection with Australian Patent Application No. 2004266160.
	2	Office Action (English translation), issued July 31, 2009, in connection with Chinese Patent Application No. 200480024125.2.
	3	Office Action (English translation), issued October 6, 2009, in connection with Japanese Patent Application No. 2006-524121.
	4	Higuchi et al., "Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones," Bioorg. Med. Chem. Lett. 17:5442-5446 (2007).


Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(g) and (h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant : Lin Zhi et al.
Serial No. : 10/566,569
Filed : August 21, 2006

Attorney's Docket No.: 3800024.00350 /1111US
Supplemental Information Disclosure Statement

Applicant respectfully requests that the Examiner review the foregoing references and they be made of record in the file history of the above-captioned application.

Respectfully submitted,



Stephanie Seidman
Reg. No. 33,779

Attorney Docket No. 3800024.00350/1111US
Address all correspondence to: 77202
Stephanie Seidman
K&L Gates LLP
3580 Carmel Mountain Road, Suite 200
San Diego, California 92130
Telephone: (858) 509-7410
Facsimile: (858) 509-7460
email: stephanie.seidman@klgates.com